198 related articles for article (PubMed ID: 19229476)
1. Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Lee KS; Ro J; Lee ES; Kang HS; Kim SW; Nam BH; Kwon Y; Kim EA; Shin KH
Invest New Drugs; 2010 Feb; 28(1):83-90. PubMed ID: 19229476
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Im SA; Lee KS; Ro J; Lee ES; Kwon Y; Ahn JH; Ahn JS; Kim JH; Kang HS; Shin KH; Noh DY; Park IA; Kim SB; Im YH; Ha SW
Breast Cancer Res Treat; 2012 Apr; 132(2):589-600. PubMed ID: 22094934
[TBL] [Abstract][Full Text] [Related]
3. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A; Dueñas-García R; Jaén-Morago A; Carrasco E; Chacón I; García-Tapiador AM; Ortega-Granados AL; Martínez-Ortega E; Ribelles N; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Martínez J; Tortosa CR; Martín-Salvago MD; Sánchez-Rovira P
Am J Clin Oncol; 2010 Oct; 33(5):432-7. PubMed ID: 19952716
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Yardley DA; Zubkus J; Daniel B; Inhorn R; Lane CM; Vazquez ER; Naot Y; Burris HA; Hainsworth JD
Clin Breast Cancer; 2010 Oct; 10(5):367-72. PubMed ID: 20670921
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
[TBL] [Abstract][Full Text] [Related]
8. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
10. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G; Christodoulou C; Tsavdaridis D; Kalogera-Fountzila A; Aravantinos G; Razis E; Kalofonos HP; Papakostas P; Karina M; Gogas H; Skarlos D
Cancer Invest; 2004; 22(5):655-62. PubMed ID: 15581045
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Miller KD; Sisk J; Ansari R; Gize G; Nattam S; Pennington K; Monaco F; Sledge GW
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):38-40. PubMed ID: 11252888
[TBL] [Abstract][Full Text] [Related]
13. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Colomer R; Llombart-Cussac A; Lluch A; Barnadas A; Ojeda B; Carañana V; Fernández Y; García-Conde J; Alonso S; Montero S; Hornedo J; Guillem V
Ann Oncol; 2004 Feb; 15(2):201-6. PubMed ID: 14760109
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
Rau KM; Li SH; Chen SM; Tang Y; Huang CH; Wu SC; Chen YY
Jpn J Clin Oncol; 2011 Apr; 41(4):455-61. PubMed ID: 21193489
[TBL] [Abstract][Full Text] [Related]
15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
[TBL] [Abstract][Full Text] [Related]
18. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
19. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Bhatia S; Hanna N; Ansari R; Pletcher W; Einhorn L; Ng E; Sandler A
Lung Cancer; 2002 Oct; 38(1):73-7. PubMed ID: 12367796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
